[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].

Autor:	Sivertseva SA; AO MSCH «Neftyanik», Tyumen, Russia.; Ural State Medical University, Yekaterinburg, Russia.; Kirov State Medical University, Kirov, Russia., Prilenskaya AM; AO MSCH «Neftyanik», Tyumen, Russia., Popova EV; City Clinical Hospital No. 24 of Moscow, Moscow, Russia.; Pirogov Russian National Research University, Moscow, Russia., Turova EL; Sverdlovsk Regional Clinical Hospital No. 1, Yekaterinburg, Russia., Volkova LI; Ural State Medical University, Yekaterinburg, Russia.; Sverdlovsk Regional Clinical Hospital No. 1, Yekaterinburg, Russia., Smagina IV; Altai State Medical University, Barnaul, Russia., Elchaninova EY; Altai State Medical University, Barnaul, Russia., Afanas'eva AI; Altai State Medical University, Barnaul, Russia., Goncharova ZA; Rostov State Medical University, Rostov-on-Don, Russia., Markova EA; Rostov State Medical University, Rostov-on-Don, Russia., Yarosh NM; Rostov State Medical University, Rostov-on-Don, Russia., Bakhtiiarova KZ; Bashkir State Medical University, Ufa, Russia., Sherman MA; Kirov State Medical University, Kirov, Russia., Boyko AN; Pirogov Russian National Research University, Moscow, Russia.; Federal Center of Brain and Neurotechnologies, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (9), pp. 76-82.
DOI:	10.17116/jnevro202312309176
Abstrakt:	Objective: To evaluate the severity and frequency of infusion reactions (IR) in patients with highly active relapsing-remitting multiple sclerosis (MS) In Russian population receiving alemtuzumab therapy. Material and Methods: In retrospective study, we analyzed data from 50 patients with highly active relapsing-remitting multiple sclerosis (MS) from six Regional MS Centers in the Russian Federation who received two courses of alemtuzumab between 2018 and 2022. Results: Among all IRs, the most frequently reported were hives-like rashes, which were registered in 27 people, mostly of mild severity (70.6%). Headaches were the second most common IR, observed in 17 patients (34%). When comparing the group of patients who underwent music therapy (MT) with those who received alemtuzumab therapy without MT, no statistically significant difference was found in the frequency and severity of IRs. Conclusion: All patients experienced IRs of varying degrees of severity. A decrease in the score on the EDSS disability scale was noted. MT did not affect the occurrence or severity of IRs.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu